A study for interventions of integrated traditional Chinese and Western medicine in the treatment of patients with the risk of coronary artery damageable

Study for early diagnosis and integrated therapy of traditional Chinese and Western medicine for the damageable keloid on coronary artery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-06000007

Enrollment

Unknown

Registered

2006-11-22

Start date

2006-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

High dose group:Atorvastatin 40 mg/d

Integrated atorvastatin and Qiongshao capsule group:Atorvastatin 20 mg/d plus Qiongshao capsule 2 pieces/time, t.i.d

Standard dose of atorvastatin group:Atorvastatin 20 mg/d

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. males and non pregnancy women who older than 18 and younger than 80 year;2. patients with unstable angina;3. coronary arteriography shown that any non-PCI vascular, main branch of coronary artery narrowed >20% of calibre; local pathologic changing and at least one branch narrowed <70% of calibre;4. target artery calibre QCA analysis =2.25mm;5. patients who willing accept to be follow-up;6. patient who should sign an agreement.

Exclusion criteria

Exclusion criteria: 1. patients with ST segment acute myocardial infarction; 2. patients complicated with valve condition; 3. patients complicated with cardiac muscle condition; 4. patients re-narrowed after bracket operation; 5. patient was accepted coronary bypass transplant; 6. coronary occlusion (TIMI 0 grade) 7. left ventricular ejection score<30%; 8. patient with fever or cough in last 48 hours; 9. inflammations, immune system diseases, connective tissue diseases; 10. patient with renal function deficiency; 11. patient with liver function deficiency; 12. patient with central neural organic disease; 13. acceptor of heart transplant; 14. patient with late cancer; 15. patient with multiple organics function failure; 16. patient whose expected life less than 3 years; 17. patient accepted other interventions in last 30 days; 18. patient who cannot obey the protocol and cannot complete the follow-up.

Design outcomes

Primary

Measure	Time frame
Change of the keloid;	—

Secondary

Measure	Time frame
Blood lipid concentration;Biomarkers;	—

Countries

China

Contacts

Public ContactLv Shuzheng

shuzheng@medmail.com.cn+86 010 64456981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026